Bimagrumab: Side Effects
Known side effects, contraindications, and interactions
๐TL;DR
- โข4 known side effects documented
- โข4 mild, 0 moderate, 0 severe
- โข3 contraindications listed
Compare side effects across multiple peptides โ
Side Effects Severity Chart
The most frequently reported adverse event across bimagrumab clinical trials. Muscle spasms are consistent with the mechanism of activin type II receptor blockade and enhanced muscle contractility. Generally mild and manageable without dose modification.
Reported across multiple bimagrumab studies. GI effects may be related to activin signaling in the GI tract. In combination with semaglutide, diarrhea was consistent with both drugs' known profiles.
Skin-related adverse effect observed in bimagrumab studies. May be related to androgen-like effects of blocking activin signaling, which normally has anti-proliferative effects on sebaceous glands.
Involuntary muscle movements reported in some participants, likely related to the mechanism of enhanced muscle excitability from activin receptor blockade.
โContraindications
- โขBimagrumab has not been approved for any indication. Formal contraindications have not been established. The following are theoretical considerations from clinical trial exclusion criteria.
- โขConditions involving TGF-beta superfamily signaling (e.g., hereditary hemorrhagic telangiectasia) may be affected by ActRII blockade.
- โขPregnancy and breastfeeding, as activin signaling plays critical roles in reproductive biology and fetal development.
โ ๏ธDrug Interactions
- โขGLP-1 receptor agonists (semaglutide, tirzepatide) have been studied in combination with bimagrumab. The BELIEVE trial showed the combination was generally well-tolerated with adverse events consistent with individual drug profiles and no new safety signals.
- โขTheoretical interaction with other TGF-beta pathway modulators (e.g., luspatercept, sotatercept) given overlapping receptor targets.
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 40+ community reports
View community protocolsClinical Trial Safety Data#
Unlike most peptides on this site, bimagrumab has been evaluated in multiple placebo-controlled clinical trials with hundreds of participants. The safety profile is therefore better characterized than most investigational compounds, though long-term data beyond 52 weeks remains limited.
Reported Side Effects#
Most Common Adverse Events#
| Side Effect | Severity | Frequency | Mechanism |
|---|---|---|---|
| Muscle spasms | Mild | Common | Enhanced muscle contractility from ActRII blockade |
| Diarrhea | Mild | Common | Activin signaling in GI tract |
| Acne | Mild | Common | Possible anti-activin effects on sebaceous glands |
| Involuntary muscle contractions | Mild | Uncommon | Increased muscle excitability |
Safety in Combination with Semaglutide (BELIEVE)#
The BELIEVE Phase 2b trial evaluated bimagrumab in combination with semaglutide in 507 participants:
- No new safety signals identified with the combination
- Adverse events were consistent with known profiles of individual drugs
- Bimagrumab-related events: muscle spasms, diarrhea, acne
- Semaglutide-related events: nausea, diarrhea, constipation, fatigue
- The combination did not amplify the severity of individual drug side effects
Safety in Inclusion Body Myositis (RESILIENT)#
In the largest IBM trial (n=251):
- Good safety profile relative to placebo across all dose levels (1, 3, 10 mg/kg)
- No dose-related safety concerns identified
- Well-tolerated in a population with neuromuscular disease
Safety in Sarcopenia (Older Adults)#
In the Rooks et al. proof-of-concept (n=40, age 65+):
- Well-tolerated at the highest dose studied (30 mg/kg)
- No serious safety concerns in the elderly population
Theoretical Concerns#
TGF-Beta Superfamily Effects#
Bimagrumab blocks signaling by multiple TGF-beta superfamily ligands, not just myostatin. This broader blockade raises theoretical concerns:
| Pathway | Normal Function | Theoretical Risk |
|---|---|---|
| BMP-9/10 signaling | Vascular homeostasis | Potential vascular effects |
| Activin A | Reproductive biology | Fertility effects |
| GDF-11 | Aging/tissue homeostasis | Unknown long-term effects |
| FSH regulation | Follicle-stimulating hormone | Reproductive hormones |
Immunogenicity#
As a monoclonal antibody, bimagrumab has the potential to induce anti-drug antibodies (ADAs). Clinical trials have monitored for ADA formation, though detailed immunogenicity data from all trials has not been comprehensively published in the obesity context.
Overall Safety Assessment#
| Assessment Criterion | Rating | Basis |
|---|---|---|
| Short-term tolerability | Good | Consistent across multiple trials |
| Severity of common AEs | Mild | Muscle spasms, diarrhea, acne |
| Dose-response safety | Reassuring | No clear dose-dependent toxicity in RESILIENT |
| Combination safety | Favorable | BELIEVE showed no new safety signals |
| Long-term safety | Unknown | Limited data beyond 52 weeks |
| Reproductive safety | Unknown | TGF-beta superfamily involved in reproduction |
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Bimagrumab
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.